Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
131.15
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,052
Open
131.15
Bid (Size)
130.45 (500)
Ask (Size)
131.99 (100)
Prev. Close
131.15
Today's Range
131.15 - 131.15
52wk Range
108.46 - 157.29
Shares Outstanding
1,253,809,440
Dividend Yield
2.50%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
SpaceX Could Swing $204 Billion After Earnings
↗
August 03, 2026
Earnings set for tight window on Tuesday, Benzinga Pro data show options pricing 3.19% move for Pfizer and 5.15% for Amgen and Gilead Sciences.
Via
Benzinga
Merck Spotlights Weekly HIV Treatment, Monthly PrEP as $5B Growth Opportunity
↗
August 03, 2026
Merck & Co., Inc. (NYSE:MRK) outlined its HIV treatment and prevention strategy at an investor event following the International AIDS Conference, highlighting Phase III results for a once-weekly oral...
Via
MarketBeat
Performance
YTD
+7.9%
+7.9%
1 Month
+1.2%
+1.2%
3 Month
-1.2%
-1.2%
6 Month
-8.2%
-8.2%
1 Year
+14.5%
+14.5%
More News
Read More
Compugen Q2 Earnings Call Highlights
↗
August 03, 2026
Via
MarketBeat
Topics
Earnings
Eli Lilly Could Swing Over $76 Billion In Value After Earnings
↗
August 03, 2026
Via
Benzinga
Gilead Sciences Inc (NASDAQ:GILD): A Quality Dividend Stock for Income Investors
↗
July 24, 2026
Via
Chartmill
Gilead Sciences (GILD) Q2 Earnings Report Preview: What To Look For
August 02, 2026
Via
StockStory
Topics
Artificial Intelligence
2 Large-Cap Stocks for Long-Term Investors and 1 Facing Challenges
July 31, 2026
Via
StockStory
Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial
↗
July 28, 2026
Via
Benzinga
Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees
↗
July 28, 2026
Via
The Motley Fool
Topics
ETFs
Global Prophylactic HIV Drug Market Growing at 7.8% CAGR Through 2034
↗
July 27, 2026
Via
Talk Markets
CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
July 24, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026?
↗
July 23, 2026
Via
The Motley Fool
Topics
ETFs
Is the iShares Healthcare ETF or the Invesco Nasdaq Biotech ETF the Better Bet for Investors in 2026?
↗
July 22, 2026
Via
The Motley Fool
Topics
ETFs
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
July 21, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill
↗
July 21, 2026
Via
Benzinga
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
July 21, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
July 21, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
3 Market-Beating Stocks with Solid Fundamentals
July 21, 2026
Via
StockStory
Topics
Energy
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
↗
July 20, 2026
Via
Benzinga
IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now?
↗
July 19, 2026
Via
The Motley Fool
Topics
ETFs
IXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy?
↗
July 18, 2026
Via
The Motley Fool
Topics
ETFs
Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move.
↗
July 17, 2026
Via
Investor's Business Daily
Topics
Intellectual Property
Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings
↗
July 16, 2026
Via
Benzinga
Invesco Healthcare ETF vs VanEck Biotech: Which ETF Will Deliver the Healthiest Returns for 2026?
↗
July 14, 2026
Via
The Motley Fool
Topics
ETFs
Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1
July 13, 2026
Via
StockStory
Topics
Artificial Intelligence
Frequently Asked Questions
Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 131.15
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 08/03/26 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 164.44B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 164B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.